Kennard C D, Ellis C N
Department of Dermatology, University of Michigan Medical Center, Ann Arbor 48109-0314.
J Am Acad Dermatol. 1991 Jul;25(1 Pt 2):176-87; discussion 188-9. doi: 10.1016/s0190-9622(08)80467-7.
Treatment of chronic urticaria presents a challenge to both practitioner and patient. Traditional H1 antagonists with good efficacy but substantial side effects are being supplanted in many cases by nonsedating H1 antagonists such as terfenadine and astemizole. Antidepressant medications and combinations of H1 and H2 antagonists offer improved results for selected patients. Further development and investigation of mast cell stabilizers and inhibitors of urticaria mediators other than histamine hold promise. A better understanding of the underlying pathogenesis remains the greatest hope of formulating rational and effective therapy.
慢性荨麻疹的治疗对医生和患者来说都是一项挑战。许多情况下,疗效良好但副作用较大的传统H1拮抗剂正被非镇静性H1拮抗剂(如特非那定和阿司咪唑)所取代。抗抑郁药物以及H1和H2拮抗剂的联合使用为部分患者带来了更好的治疗效果。肥大细胞稳定剂和除组胺外的荨麻疹介质抑制剂的进一步研发和研究前景广阔。更好地理解潜在发病机制仍是制定合理有效治疗方案的最大希望。